North America is expected to dominate the Overall Autoinjectors Market:
Among all the regions, North America is expected to account for the largest share in the autoinjectors market. The North American Autoinjectors market is predicted to grow due to the rising demand for autoinjector devices in facilitating self-administration of drugs, the presence of highly aware patient pool, as well as better healthcare access in the region.
In North America, the US is expected to account for the largest share in of the North American Autoinjectors market. This can be attributed to the increasing cases of indications such as rheumatoid arthritis, migraine, MS, and anaphylaxis among others.
As per the data provided by the Migraine Research Foundation (2021), approximately 39 million people including both children and adult populations suffer from migraine in the country. It further stated that more than 4 million people experience chronic migraine episodes on a daily basis. Migraine is an extremely debilitating neurological illness which leaves over 90% of sufferers in a compromised state unable to work or function normally during their migraine.
Furthermore, according to the National Multiple Sclerosis Society, United States, in 2021, it has been estimated that about one million people are currently living in the country with MS, which is twice the number than previous estimates. These indications among others can drastically affect the quality of life of patients and more so often require urgent administration of the therapeutic drug in events of sporadic onset of an episode.
Moreover, the US Food and Drug Administration (FDA) is a highly active regulatory body which focuses on not only on the careful regulation of the approval processes of the medical devices and pharmaceutical products but also engages extensively in educating patients and caregivers regarding new treatment methods, products, and even adversities related to them. This has resulted in the presence of highly aware patient population in the country.
Additionally, the large presence of key market players in the country as well as the launch of new products in the country also provide favorable conditions for the growth of the Autoinjectors market in the region.
In August 2020, the US FDA approved Kesimpta® (as an injection for subcutaneous use for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It is the first B-cell therapy which can be self-administered by patients via the Sensoready autoinjector pen.
Therefore, owing to the above-mentioned factors, the market for autoinjectors in the United States and North America is predicted to witness significant growth in the forecast period.
What are the Autoinjectors Companies?
Some of the key market players operating in the autoinjectors market includes BD, Ysmoed AG, Sonceboz, Phillips-Medisize, Nemera, Novartis, Teva Pharmaceuticals, Amgen, GSK, Mylan Inc, Elcam Medical, Union Medico Injection Safety ApS, SHL Medical AG, Haselmeier, Owen Mumford Ltd, and others.